BIOE Trademark

Trademark Overview


On Tuesday, August 13, 2019, a trademark application was filed for BIOE with the United States Patent and Trademark Office. The USPTO has given the BIOE trademark a serial number of 88577146. The federal status of this trademark filing is ABANDONED - FAILURE TO RESPOND OR LATE RESPONSE as of Tuesday, August 23, 2022. This trademark is owned by Truetiva, Inc.. The BIOE trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical agents affecting digestive organs; Pharmaceutical agents affecting metabolism; Pharmaceutical agents for epidermis; Pharmaceutical preparation for skin care; Pharmaceutical preparation for the treatment of gout; Pharmaceutical preparations and substances for the treatment of damaged skin and tissue; Pharmaceutical preparations and substances for the treatment of gastro-intestinal diseases; Pharmaceutical preparations and substances for the treatment of infectious diseases, blood disorders, pain, inflammation, sepsis, alopecia, obesity and cognitive disorders; Pharmaceutical preparations and substances for the treatment of psychiatric diseases and disorders; Pharmaceutical preparations and substances for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system ...
bioe

General Information


Serial Number88577146
Word MarkBIOE
Filing DateTuesday, August 13, 2019
Status602 - ABANDONED - FAILURE TO RESPOND OR LATE RESPONSE
Status DateTuesday, August 23, 2022
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateNOT AVAILABLE

Trademark Statements


Goods and ServicesPharmaceutical agents affecting digestive organs; Pharmaceutical agents affecting metabolism; Pharmaceutical agents for epidermis; Pharmaceutical preparation for skin care; Pharmaceutical preparation for the treatment of gout; Pharmaceutical preparations and substances for the treatment of damaged skin and tissue; Pharmaceutical preparations and substances for the treatment of gastro-intestinal diseases; Pharmaceutical preparations and substances for the treatment of infectious diseases, blood disorders, pain, inflammation, sepsis, alopecia, obesity and cognitive disorders; Pharmaceutical preparations and substances for the treatment of psychiatric diseases and disorders; Pharmaceutical preparations and substances for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; Pharmaceutical preparations for inhalation for the treatment of pulmonary hypertension; Pharmaceutical preparations for skin care; Pharmaceutical preparations for skin wounds; Pharmaceutical preparations for the treatment of heart rhythm disorders; Pharmaceutical preparations for the treatment of immune system related diseases and disorders; Pharmaceutical preparations for the treatment of kidney diseases; Pharmaceutical preparations for treating allergic rhinitis and asthma; Pharmaceutical preparations for treating allergies; Pharmaceutical preparations for treating and preventing tendon and muscle injuries and disorders, sports related injuries, and for knee cartilage regeneration; Pharmaceutical preparations for treating chemical imbalances; Pharmaceutical preparations for treating diabetes; Pharmaceutical preparations for treating hypertension; Pharmaceutical preparations for use in chemotherapy; Pharmaceutical preparations for use in dermatology; Pharmaceutical preparations, namely, an analgesic for human consumption taken orally; Pharmaceutical preparations, namely, antivirals; Pharmaceutical preparations, namely, appetite suppressants; Pharmaceutical products and preparations to prevent stretch marks; Pharmaceutical products for the prevention and treatment of cancer; Pharmaceutical products for the treatment of joint disease; Pharmaceutical products for the treatment of viral and infectious diseases, for the treatment of cancer; Pharmaceutical products for treating respiratory diseases; Pharmaceutical products for treating respiratory diseases and asthma; Pharmaceutical skin lotions; Pharmaceuticals, namely, anti-infectives; Pharmaceuticals, namely, lipid lowering agents; Balms for pharmaceutical purposes; Dermatological pharmaceutical products; Digestives for pharmaceutical purposes; Plant extracts for pharmaceutical purposes
Pseudo MarkBIO E

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateWednesday, August 28, 2019
Primary Code005
First Use Anywhere DateFriday, March 15, 2019
First Use In Commerce DateFriday, March 15, 2019

Trademark Owner History


Party NameTruetiva, Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressGrand Rapids, MI 49503

Trademark Events


Event DateEvent Description
Wednesday, August 24, 2022ABANDONMENT NOTICE E-MAILED - FAILURE TO RESPOND
Tuesday, August 23, 2022ABANDONMENT NOTICE MAILED - FAILURE TO RESPOND
Tuesday, August 23, 2022ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE
Wednesday, August 17, 2022ASSIGNED TO EXAMINER
Monday, January 10, 2022NOTIFICATION OF NON-FINAL ACTION E-MAILED
Monday, January 10, 2022NON-FINAL ACTION E-MAILED
Monday, January 10, 2022NON-FINAL ACTION WRITTEN
Monday, February 15, 2021TEAS/EMAIL CORRESPONDENCE ENTERED
Monday, February 15, 2021CORRESPONDENCE RECEIVED IN LAW OFFICE
Monday, February 15, 2021TEAS RESPONSE TO OFFICE ACTION RECEIVED
Friday, August 14, 2020NOTIFICATION OF NON-FINAL ACTION E-MAILED
Friday, August 14, 2020NON-FINAL ACTION E-MAILED
Friday, August 14, 2020NON-FINAL ACTION WRITTEN
Thursday, August 6, 2020ASSIGNED TO EXAMINER
Tuesday, November 12, 2019ASSIGNED TO EXAMINER
Tuesday, November 12, 2019ASSIGNED TO EXAMINER
Wednesday, August 28, 2019NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM
Friday, August 16, 2019NEW APPLICATION ENTERED IN TRAM